Foley Hoag LLP represented Ginkgo Bioworks on the agreement. Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug...
Ginkgo Bioworks’ Collaboration Agreement with Pfizer
Alcyone’s License and Collaboration Agreement with Biogen Inc.
Foley Hoag LLP represented Alcyone Therapeutics on the deal. Alcyone Therapeutics (Alcyone) announced the negotiation of a license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) to...
Ginkgo Bioworks’ Collaboration Agreement with Merck
Foley Hoag LLP represented Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, closed a collaboration agreement with...
Ginkgo Bioworks’ Collaboration with Novo Nordisk
Foley Hoag LLP represented Ginkgo Bioworks, Inc. on the deal. Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, closed a collaboration agreement with...
Intellia Therapeutics’ Acquisition of a Stake in SparingVision
IN BRIEF: Bird & Bird, Foley Hoag LLP, Goodwin Procter, advised on the matter. Bird & Bird advised SparingVision SAS with a team including Emmanuelle Porte...
Ginkgo Bioworks’ Collaboration and License Agreement with Biogen
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
Ginkgo Bioworks’ Collaboration and License Agreement with Biogen
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
Alloy Therapeutics’ $75M Series C Financing
Foley Hoag LLP advised Alloy Therapeutics on the deal. Alloy Therapeutics announced a $75 million Series C Financing. Proceeds from the Series C financing will support the...